NO20006328L - Attenuerte negative tradvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter - Google Patents

Attenuerte negative tradvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter

Info

Publication number: NO20006328L
Authority: NO; Norway
Prior art keywords: viruses; attenuated; vaccines; trad; drugs
Prior art date: 1998-06-12

Application number

NO20006328A

Other languages

English (en)

Other versions

NO20006328D0 (no

Inventor

Peter Palese

Adolfo Garcia-Sastre

Thomas Muster

Original Assignee

Sinai School Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

2000-12-12

Publication date

2001-02-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27376229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006328(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-12 Application filed by Sinai School Medicine filed Critical Sinai School Medicine

2000-12-12 Publication of NO20006328D0 publication Critical patent/NO20006328D0/no

2001-02-02 Publication of NO20006328L publication Critical patent/NO20006328L/no

Links

241000700605 Viruses Species 0.000 title abstract 5
230000002238 attenuated effect Effects 0.000 title abstract 5
102000014150 Interferons Human genes 0.000 title abstract 4
108010050904 Interferons Proteins 0.000 title abstract 4
229940079322 interferon Drugs 0.000 title abstract 4
229960005486 vaccine Drugs 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
230000000694 effects Effects 0.000 title 1
101150033828 NS1 gene Proteins 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
230000001413 cellular effect Effects 0.000 abstract 1
230000010479 cellular ifn response Effects 0.000 abstract 1
230000002950 deficient Effects 0.000 abstract 1
241001493065 dsRNA viruses Species 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
230000007918 pathogenicity Effects 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
241000712461 unidentified influenza virus Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16241—Use of virus, viral particle or viral elements as a vector
- C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16261—Methods of inactivation or attenuation
- C12N2760/16262—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20006328A 1998-06-12 2000-12-12 Attenuerte negative tradvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter NO20006328L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US8910398P	1998-06-12	1998-06-12
US10883298P	1998-11-18	1998-11-18
US11768399P	1999-01-29	1999-01-29
PCT/US1999/013144 WO1999064068A1 (en)	1998-06-12	1999-06-11	Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

Publications (2)

Publication Number	Publication Date
NO20006328D0 NO20006328D0 (no)	2000-12-12
NO20006328L true NO20006328L (no)	2001-02-02

Family

ID=27376229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006328A NO20006328L (no)	1998-06-12	2000-12-12	Attenuerte negative tradvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter

Country Status (24)

Country	Link
US (12)	US6669943B1 (no)
EP (4)	EP1086207B1 (no)
JP (7)	JP4837827B2 (no)
KR (2)	KR20060080249A (no)
CN (1)	CN1312725A (no)
AT (1)	ATE351901T1 (no)
AU (2)	AU770619B2 (no)
BR (1)	BR9911163A (no)
CA (2)	CA2334895C (no)
CY (1)	CY1113689T1 (no)
CZ (2)	CZ302601B6 (no)
DE (1)	DE69934885T2 (no)
DK (4)	DK2316923T3 (no)
ES (4)	ES2400445T3 (no)
HU (1)	HUP0102441A3 (no)
IL (6)	IL140264A0 (no)
MX (2)	MXPA00012402A (no)
NO (1)	NO20006328L (no)
NZ (2)	NZ509054A (no)
PL (3)	PL200977B1 (no)
PT (1)	PT1085904E (no)
RU (1)	RU2236252C2 (no)
SK (3)	SK288200B6 (no)
WO (2)	WO1999064068A1 (no)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2905284B2 (ja)	1989-11-06	1999-06-14	株式会社日本触媒	アクリル酸の製造方法
US7780962B2 (en)	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
US7470426B1 (en)	1997-10-09	2008-12-30	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
DK2316923T3 (en) *	1998-06-12	2018-01-08	Icahn School Med Mount Sinai	Attenuated influenza viruses with altered interferon antagonist activity for use as vaccines and drugs
MXPA01010393A (es) *	1999-04-15	2004-04-02	Pro Virus Inc	Tratamiento de neoplasmas con virus.
ES2320239T3 (es)	1999-09-17	2009-05-20	Wellstat Biologics Corporation	Virus oncolitico.
US8147822B1 (en)	1999-09-17	2012-04-03	Wellstat Biologics Corporation	Oncolytic virus
AU2001250352B2 (en) *	2000-03-02	2006-01-12	Polymun Scientific Immunbiologische Forschung Gmbh	Recombinant influenza a viruses
WO2001077394A1 (en)	2000-04-10	2001-10-18	Mount Sinai School Of Medicine Of New York University	Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) *	2000-04-26	2001-10-31	Conzelmann Karl Klaus	RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
KR20030061810A (ko) *	2000-09-25	2003-07-22	폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하	생균 백신과 제조 방법
US7311904B2 (en)	2001-02-14	2007-12-25	Anthrogenesis Corporation	Tissue matrices comprising placental stem cells, and methods of making the same
WO2002094423A1 (en)	2001-05-22	2002-11-28	Access Business Group International Llc	Method and apparatus for blending and dispensing liquid compositions
DE50205128D1 (de) *	2001-07-16	2006-01-05	Greenhills Biotechnology Res D	Verwendung einer antiviralen verbindungsklasse (dithiocarbamat-verbindungen) zur herstellung eines mittels zur behandlung bzw. prävention einer virusinfektion im respiratorischen trakt
US7037707B2 (en) *	2003-09-04	2006-05-02	St. Jude Children's Research Hospital	Method for generating influenza viruses and vaccines
US8124101B2 (en) *	2004-06-01	2012-02-28	Mount Sinai School Of Medicine	Genetically engineered swine influenza virus and uses thereof
US8137676B2 (en)	2005-02-15	2012-03-20	Mount Sinai School Of Medicine	Genetically engineered equine influenza virus and uses thereof
AT502275B8 (de) *	2005-08-08	2007-08-15	Greenhills Biotechnology Res D	Immunantwort-induzierende zusammensetzungen
EP2251034B1 (en)	2005-12-02	2018-02-14	Icahn School of Medicine at Mount Sinai	Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
EP1911836A1 (en)	2006-10-12	2008-04-16	AVIR Green Hills Biotechnology Trading GmbH	Medium supplement for virus production
US7860646B2 (en) *	2007-04-16	2010-12-28	The Boeing Company	Method and apparatus for routing ocean going vessels to avoid treacherous environments
WO2008144067A1 (en) *	2007-05-21	2008-11-27	Board Of Regents, University Of Texas System	Methods and compositions for treatment of cancer using oncolytic rsv activity
EP2048237A1 (en) *	2007-10-05	2009-04-15	Avir Green Hills Biotechnology Research Development Trade Ag	Replication deficient Influenza virus for the expression of heterologous sequences
EP2045323A1 (en) *	2007-10-05	2009-04-08	Avir Green Hills Biotechnology Research Development Trade Ag	Linear expression constructs for production of influenza virus particles
EP2072058A1 (en)	2007-12-21	2009-06-24	Avir Green Hills Biotechnology Research Development Trade Ag	Modified influenza virus
US8108138B2 (en) *	2008-10-02	2012-01-31	The Boeing Company	Optimal vehicle router with energy management system
US8883479B2 (en)	2008-11-25	2014-11-11	Baxter Healthcare Sa	Method for production of pH stable enveloped viruses
EP2233568A1 (en)	2009-03-19	2010-09-29	Avir Green Hills Biotechnology Research Development Trade AG	Novel method for generation of RNA virus
ES2675771T3 (es)	2008-12-16	2018-07-12	Ology Bioservices, Inc.	Producción de vacunas contra el virus de la gripe
EP2233152A1 (en)	2009-03-24	2010-09-29	Avir Green Hills Biotechnology Research Development Trade Ag	High growth reassortant influenza A virus
US8935174B2 (en) *	2009-01-16	2015-01-13	The Boeing Company	Analyzing voyage efficiencies
ES2550179T3 (es)	2009-02-05	2015-11-05	Icahn School Of Medicine At Mount Sinai	Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
CA2787099A1 (en)	2009-03-30	2010-10-14	Anice C. Lowen	Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CA2763816A1 (en)	2009-04-27	2010-11-04	Novartis Ag	Adjuvanted vaccines for protecting against influenza
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
WO2011005765A1 (en) *	2009-07-06	2011-01-13	Alnylam Pharmaceuticals, Inc.	Bioprocessing
ES2557315T3 (es)	2009-07-22	2016-01-25	Baxalta GmbH	Nuevo virus de la gripe
US9217157B2 (en)	2009-07-27	2015-12-22	Icahn School Of Medicine At Mount Sinai	Recombinant influenza viruses and uses thereof
CA2805505C (en)	2009-07-30	2021-08-03	Mount Sinai School Of Medecine	Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
CN102666860B (zh)	2009-07-31	2015-06-17	诺华股份有限公司	反向遗传系统
EP2295543A1 (en) *	2009-09-11	2011-03-16	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Method for the preparation of an influenza virus
CN102939103A (zh)	2010-03-30	2013-02-20	西奈山医学院	流感病毒疫苗及其应用
US8597637B1 (en) *	2010-05-18	2013-12-03	Weidong Zhang	Breast cancer therapy using an engineered respiratory syncytial virus
EP2576773A2 (en)	2010-06-02	2013-04-10	Avir Green Hills Biotechnology Research Development Trade AG	Methods and helper viruses for the generation of rna virus
US9044499B1 (en)	2010-06-22	2015-06-02	Weidong Zhang	NS1/2-deficient respiratory syncytial virus and melanoma treatment
US8377901B2 (en) *	2010-07-07	2013-02-19	The University Of Manitoba	Target host factors for treating viral infection
CN102021149B (zh) *	2010-07-27	2013-04-24	张卫东	基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用
CN102021148A (zh) *	2010-07-27	2011-04-20	张卫东	一种基因ns1缺陷型呼吸道合胞病毒及其应用
KR20140068205A (ko)	2011-09-20	2014-06-05	마운트 시나이 스쿨 오브 메디슨	인플루엔자 바이러스 백신 및 이의 용도
US9157746B2 (en)	2011-11-16	2015-10-13	The Boeing Company	Vessel routing system
KR20150104117A (ko)	2012-12-18	2015-09-14	이칸 스쿨 오브 메디슨 엣 마운트 시나이	인플루엔자 바이러스 백신 및 그의 용도
CN103330723A (zh) *	2013-01-14	2013-10-02	艾克星（武汉）生物医药科技有限公司	基因工程呼吸道合胞病毒（△ns1 rsv)在治疗癌症药物中的用途
WO2014159990A1 (en)	2013-03-13	2014-10-02	Yale University	Interferon production using short rna duplexes
WO2014159960A1 (en)	2013-03-14	2014-10-02	Icahn School Of Medicine At Mount Sinai	Antibodies against influenza virus hemagglutinin and uses thereof
AU2014241843B2 (en)	2013-03-14	2019-05-02	Icahn School Of Medicine At Mount Sinai	Newcastle disease viruses and uses thereof
CN107073099B (zh)	2014-02-27	2022-09-27	默沙东公司	用于治疗癌症的联合方法
US10736956B2 (en)	2015-01-23	2020-08-11	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccination regimens
BR112017015789A2 (pt)	2015-02-26	2018-03-27	Boehringer Ingelheim Vetmedica Gmbh	vacina de vírus da influenza suína bivalente
WO2017030997A1 (en) *	2015-08-14	2017-02-23	Research Institute At Nationwide Children's Hospital	Respiratory syncytial virus having altered ns1 protein function and related materials and methods
RU2628690C2 (ru) *	2015-11-06	2017-08-21	Общество С Ограниченной Ответственностью 'Фарминтерпрайсез'	Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
RU2660562C2 (ru) *	2016-03-30	2018-07-06	Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ"	Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
EA037571B1 (ru) *	2015-11-06	2021-04-15	Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ"	Аттенуированный вирус гриппа а, аттенуированный грипозный вектор, фармацевтическая композиция и их применение для профилактики или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
CN108603188A (zh)	2015-11-24	2018-09-28	联邦科学技术研究组织	在细胞培养物中产生病毒
EP3380616A4 (en) *	2015-11-24	2019-11-06	Commonwealth Scientific and Industrial Research Organisation	MANUFACTURE OF VIRUSES IN BIRDS
WO2017218624A1 (en)	2016-06-15	2017-12-21	Icahn School Of Medicine At Mount Sinai	Influenza virus hemagglutinin proteins and uses thereof
US20190352615A1 (en)	2016-12-22	2019-11-21	Blue Sky Vaccines Gmbh	Method for purifying virus
EP3596202A4 (en)	2017-03-14	2021-01-27	The Regents of the University of California	GENOME-SCALE IDENTIFICATION OF IMMUNE EVASURE FUNCTIONS IN A VIRUS
WO2018187706A2 (en)	2017-04-07	2018-10-11	Icahn School Of Medicine At Mount Sinai	Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
CN111527202B (zh)	2017-11-08	2024-03-29	蓝天免疫疗法有限责任公司	So3色谱在病毒纯化方法中的应用
EP3810634A4 (en)	2018-06-21	2022-07-27	Icahn School of Medicine at Mount Sinai	Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020037215A1 (en)	2018-08-17	2020-02-20	Icahn School Of Medicine At Mount Sinai	Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US12350325B2 (en)	2019-01-24	2025-07-08	Vivaldi Biosciences Inc.	Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2
US12419946B2 (en)	2019-02-07	2025-09-23	Duke University	Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
KR102370100B1 (ko) *	2019-02-15	2022-03-07	아이디바이오 주식회사	이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
EP3959216A4 (en)	2019-04-24	2023-01-11	Icahn School of Medicine at Mount Sinai	ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
AU2020287915B2 (en) *	2019-06-07	2025-05-15	Intervet International B.V.	MDBK IRF3/IRF7 knock out mutant cell and its use for vaccine production
JP7222552B2 (ja) *	2020-01-30	2023-02-15	国立研究開発法人農業・食品産業技術総合研究機構	豚デルタコロナウイルスの増殖方法
CN116888139A (zh) *	2020-11-30	2023-10-13	蓝天免疫疗法有限责任公司	诱导高水平i型干扰素的新型复制缺陷型甲型流感病毒
US20240035035A1 (en) *	2020-12-09	2024-02-01	Yale University	Compositions and methods for treating, ameliorating, and/or preventing viral infections
US20240366791A1 (en)	2021-06-09	2024-11-07	Icahn School Of Medicine At Mount Sinai	Gene combination as a broad spectrum antiviral
CN115896035B (zh) *	2022-12-22	2024-04-16	苏州沃美生物有限公司	一种应用于病毒扩增的Vero细胞株、其构建方法及应用
WO2025019631A1 (en)	2023-07-19	2025-01-23	Icahn School Of Medicine At Mount Sinai	Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4071618A (en) *	1974-09-03	1978-01-31	Research Foundation For Microbial Diseases Of Osaka University	Process for preparing virus disease live vaccines
US4215051A (en)	1979-08-29	1980-07-29	Standard Oil Company (Indiana)	Formation, purification and recovery of phthalic anhydride
JPS57136528A (en) *	1981-02-09	1982-08-23	Hayashibara Biochem Lab Inc	Preparation of viral vaccine
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
JPS5939831A (ja)	1982-08-27	1984-03-05	Biseibutsu Kagaku Kenkyusho:Kk	豚用インフルエンザウイルス不活化ワクチン
US4693981A (en) *	1983-12-20	1987-09-15	Advanced Genetics Research Institute	Preparation of inactivated viral vaccines
US5106619A (en) *	1983-12-20	1992-04-21	Diamond Scientific Co.	Preparation of inactivated viral vaccines
JPS60202827A (ja) *	1984-03-28	1985-10-14	Chibaken	弱毒痘そうワクチン株
US5166057A (en) *	1989-08-28	1992-11-24	The Mount Sinai School Of Medicine Of The City University Of New York	Recombinant negative strand rna virus expression-systems
US5840520A (en) *	1989-08-28	1998-11-24	Aviron	Recombinant negative strand RNA virus expression systems
US5786199A (en)	1989-08-28	1998-07-28	The Mount Sinai School Of Medicine Of The City University Of New York	Recombinant negative strand RNA virus expression systems and vaccines
US5854037A (en) *	1989-08-28	1998-12-29	The Mount Sinai School Of Medicine Of The City University Of New York	Recombinant negative strand RNA virus expression systems and vaccines
US5766601A (en)	1990-08-08	1998-06-16	University Of Massachusetts Medical Center	Cross-reactive influenza a immunization
US6162432A (en) *	1991-10-07	2000-12-19	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
JPH07502496A (ja)	1991-10-07	1995-03-16	バイオゲン　インコーポレイテッド	Ｃｄ２／ｌｆａ−３相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法
DE570357T1 (de)	1992-05-14	1994-07-28	Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien	Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
US7344722B1 (en) *	1993-06-29	2008-03-18	The Regents Of The University Of Michigan	Cold-adapted influenza virus
EP1394259A3 (en)	1994-07-18	2004-04-14	Karl-Klaus Prof. Dr. Conzelmann	Recombinant infectious non-segmented negative strand RNA virus
US6300090B1 (en) *	1994-07-29	2001-10-09	The Rockefeller University	Methods of use of viral vectors to deliver antigen to dendritic cells
US6146873A (en) *	1994-11-10	2000-11-14	Baxter Aktiengesellschaft	Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en)	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
ATE181112T1 (de)	1995-08-09	1999-06-15	Schweiz Serum & Impfinst	Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
US5840565A (en)	1995-08-22	1998-11-24	The Regents Of The University Of California	Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6264957B1 (en)	1995-09-27	2001-07-24	The United States Of America As Represented By The Department Of Health And Human Services	Product of infectious respiratory syncytial virus from cloned nucleotide sequences
GB9605808D0 (en) *	1996-03-20	1996-05-22	Isis Innovation	CFTR gene regulator
ATE451451T1 (de)	1996-07-15	2009-12-15	Us Gov Health & Human Serv	Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
KR20000048628A (ko)	1996-09-27	2000-07-25	윌리암 에이취 캘넌, 에곤 이 버그	모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
US6330090B1 (en) *	1997-02-14	2001-12-11	Photonetics	Optical fiber wavelength, multiplexer and demultiplexer
AU726374B2 (en)	1997-03-05	2000-11-02	University Of Washington	Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
US5891705A (en) *	1997-04-08	1999-04-06	Pentose Pharmaceuticals, Inc.	Method for inactivating a virus
US6884414B1 (en) *	1997-04-30	2005-04-26	Mount Sinai School Of Medicine Of New York University	Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
CN1250725C (zh)	1997-05-23	2006-04-12	美国政府健康及人类服务部	从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
JP4434478B2 (ja)	1997-07-11	2010-03-17	イエールユニバーシティー	リエンジニアリングされた外被を有するラブドウイルス
WO1999015672A1 (en)	1997-09-19	1999-04-01	American Cyanamid Company	Attenuated respiratory syncytial viruses
EP1098961B1 (en) *	1998-06-12	2008-01-16	Mount Sinai School Of Medicine Of The City University Of New York	Interferon inducing genetically engineered attenuated viruses
DK2316923T3 (en)	1998-06-12	2018-01-08	Icahn School Med Mount Sinai	Attenuated influenza viruses with altered interferon antagonist activity for use as vaccines and drugs
US6544785B1 (en) *	1998-09-14	2003-04-08	Mount Sinai School Of Medicine Of New York University	Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) *	1998-09-14	2000-11-14	Mount Sinai School Of Medicine, Of The City University Of New York	Recombinant new castle disease virus RNA expression systems and vaccines
AT407958B (de) *	1999-02-11	2001-07-25	Immuno Ag	Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
EP1194580B2 (en)	1999-07-14	2010-08-25	Mount Sinai School of Medicine of New York University	In vitro reconstitution of segmented negative-strand rna viruses
AU2001250352B2 (en) *	2000-03-02	2006-01-12	Polymun Scientific Immunbiologische Forschung Gmbh	Recombinant influenza a viruses
WO2001077394A1 (en)	2000-04-10	2001-10-18	Mount Sinai School Of Medicine Of New York University	Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de)	2000-04-26	2001-10-31	Conzelmann Karl Klaus	RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
KR20030061810A (ko) *	2000-09-25	2003-07-22	폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하	생균 백신과 제조 방법
AUPR343601A0 (en) *	2001-02-28	2001-03-29	Dickins, Philip	Trenching machine
CA2505949A1 (en) *	2002-11-13	2004-05-27	Rutgers, The State University	Process for designing inhibitors of influenza virus non-structural protein 1
US8124101B2 (en)	2004-06-01	2012-02-28	Mount Sinai School Of Medicine	Genetically engineered swine influenza virus and uses thereof
US8137676B2 (en)	2005-02-15	2012-03-20	Mount Sinai School Of Medicine	Genetically engineered equine influenza virus and uses thereof
US20070116717A1 (en) *	2005-08-01	2007-05-24	Shneider Alexander M	Influenza vaccine compositions and methods
AT502275B8 (de) *	2005-08-08	2007-08-15	Greenhills Biotechnology Res D	Immunantwort-induzierende zusammensetzungen
EP2251034B1 (en)	2005-12-02	2018-02-14	Icahn School of Medicine at Mount Sinai	Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
US7507411B2 (en) *	2006-06-23	2009-03-24	University Of Saskatchewan	Attenuated influenza NS1 variants

1999
- 1999-06-11 DK DK10181977.9T patent/DK2316923T3/en active
- 1999-06-11 PL PL346212A patent/PL200977B1/pl not_active IP Right Cessation
- 1999-06-11 EP EP99927443A patent/EP1086207B1/en not_active Expired - Lifetime
- 1999-06-11 PL PL386473A patent/PL212316B1/pl unknown
- 1999-06-11 JP JP2000553560A patent/JP4837827B2/ja not_active Expired - Lifetime
- 1999-06-11 MX MXPA00012402A patent/MXPA00012402A/es active IP Right Grant
- 1999-06-11 DK DK10181856.5T patent/DK2316924T3/en active
- 1999-06-11 CA CA2334895A patent/CA2334895C/en not_active Expired - Lifetime
- 1999-06-11 WO PCT/US1999/013144 patent/WO1999064068A1/en not_active Ceased
- 1999-06-11 DK DK99927443T patent/DK1086207T3/da active
- 1999-06-11 NZ NZ509054A patent/NZ509054A/en not_active IP Right Cessation
- 1999-06-11 MX MXPA00012403A patent/MXPA00012403A/es active IP Right Grant
- 1999-06-11 AT AT99927443T patent/ATE351901T1/de active
- 1999-06-11 IL IL14026499A patent/IL140264A0/xx active IP Right Grant
- 1999-06-11 WO PCT/US1999/013142 patent/WO1999064570A1/en not_active Ceased
- 1999-06-11 SK SK1907-2000A patent/SK288200B6/sk not_active IP Right Cessation
- 1999-06-11 ES ES99927445T patent/ES2400445T3/es not_active Expired - Lifetime
- 1999-06-11 EP EP10181856.5A patent/EP2316924B1/en not_active Expired - Lifetime
- 1999-06-11 ES ES10181856.5T patent/ES2650500T3/es not_active Expired - Lifetime
- 1999-06-11 SK SK50041-2015A patent/SK288544B6/sk not_active IP Right Cessation
- 1999-06-11 DK DK99927445.9T patent/DK1085904T3/da active
- 1999-06-11 PL PL398576A patent/PL219128B1/pl unknown
- 1999-06-11 CZ CZ20004635A patent/CZ302601B6/cs not_active IP Right Cessation
- 1999-06-11 EP EP99927445A patent/EP1085904B1/en not_active Expired - Lifetime
- 1999-06-11 NZ NZ509055A patent/NZ509055A/xx not_active IP Right Cessation
- 1999-06-11 CA CA2334850A patent/CA2334850C/en not_active Expired - Lifetime
- 1999-06-11 AU AU44345/99A patent/AU770619B2/en not_active Expired
- 1999-06-11 HU HU0102441A patent/HUP0102441A3/hu not_active Application Discontinuation
- 1999-06-11 KR KR1020067011483A patent/KR20060080249A/ko not_active Ceased
- 1999-06-11 US US09/332,288 patent/US6669943B1/en not_active Expired - Lifetime
- 1999-06-11 ES ES99927443T patent/ES2281177T3/es not_active Expired - Lifetime
- 1999-06-11 CN CN99809582A patent/CN1312725A/zh active Pending
- 1999-06-11 AU AU44343/99A patent/AU771110B2/en not_active Ceased
- 1999-06-11 RU RU2001101426/15A patent/RU2236252C2/ru active IP Right Revival
- 1999-06-11 CZ CZ2011-316A patent/CZ306637B6/cs not_active IP Right Cessation
- 1999-06-11 JP JP2000553136A patent/JP4531255B2/ja not_active Expired - Lifetime
- 1999-06-11 BR BR9911163-2A patent/BR9911163A/pt not_active IP Right Cessation
- 1999-06-11 EP EP10181977.9A patent/EP2316923B1/en not_active Expired - Lifetime
- 1999-06-11 KR KR1020007014088A patent/KR100637937B1/ko not_active Expired - Lifetime
- 1999-06-11 ES ES10181977.9T patent/ES2653557T3/es not_active Expired - Lifetime
- 1999-06-11 DE DE69934885T patent/DE69934885T2/de not_active Expired - Lifetime
- 1999-06-11 SK SK50021-2008A patent/SK288567B6/sk not_active IP Right Cessation
- 1999-06-11 IL IL14026599A patent/IL140265A0/xx active IP Right Grant
- 1999-06-11 US US09/332,286 patent/US6573079B1/en not_active Expired - Lifetime
- 1999-06-11 PT PT99927445T patent/PT1085904E/pt unknown
2000
- 2000-11-28 US US09/724,419 patent/US6852522B1/en not_active Expired - Lifetime
- 2000-12-12 IL IL140265A patent/IL140265A/en not_active IP Right Cessation
- 2000-12-12 NO NO20006328A patent/NO20006328L/no not_active Application Discontinuation
- 2000-12-12 IL IL140264A patent/IL140264A/en not_active IP Right Cessation
2003
- 2003-11-14 US US10/713,732 patent/US7588768B2/en not_active Expired - Lifetime
2004
- 2004-09-20 US US10/945,718 patent/US7494808B2/en not_active Expired - Fee Related
2007
- 2007-12-24 IL IL188362A patent/IL188362A0/en not_active IP Right Cessation
2008
- 2008-02-26 IL IL189766A patent/IL189766A0/en unknown
- 2008-04-22 US US12/148,798 patent/US8057803B2/en not_active Expired - Fee Related
2009
- 2009-02-02 US US12/364,243 patent/US9352033B2/en not_active Expired - Fee Related
- 2009-02-23 US US12/391,172 patent/US20100233785A1/en not_active Abandoned
- 2009-06-08 US US12/480,410 patent/US20100158942A1/en not_active Abandoned
- 2009-12-16 JP JP2009285467A patent/JP5081220B2/ja not_active Expired - Lifetime
2010
- 2010-02-12 JP JP2010029288A patent/JP2010142248A/ja active Pending
- 2010-09-29 JP JP2010218868A patent/JP2011050384A/ja active Pending
2011
- 2011-09-30 US US13/250,846 patent/US8765139B2/en not_active Expired - Fee Related
2013
- 2013-02-15 CY CY20131100144T patent/CY1113689T1/el unknown
- 2013-06-26 JP JP2013133432A patent/JP5810134B2/ja not_active Expired - Lifetime
- 2013-08-16 JP JP2013169102A patent/JP5829655B2/ja not_active Expired - Lifetime
2014
- 2014-05-22 US US14/285,339 patent/US9387240B2/en not_active Expired - Fee Related
2016
- 2016-06-08 US US15/176,721 patent/US20160279227A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100233785A1 (en)	2010-09-16
IL188362A0 (en)	2008-03-20
US7588768B2 (en)	2009-09-15
RU2236252C2 (ru)	2004-09-20
CY1113689T1 (el)	2016-06-22
WO1999064570A9 (en)	2000-03-09
JP2011050384A (ja)	2011-03-17
EP2316923A3 (en)	2014-04-09
WO1999064068A1 (en)	1999-12-16
JP5829655B2 (ja)	2015-12-09
US8057803B2 (en)	2011-11-15
JP2010142248A (ja)	2010-07-01
PL212316B1 (pl)	2012-09-28
JP4837827B2 (ja)	2011-12-14
US20050054074A1 (en)	2005-03-10
IL189766A0 (en)	2008-08-07
PL346212A1 (en)	2002-01-28
US20090053264A1 (en)	2009-02-26
MXPA00012402A (es)	2003-07-14
ES2650500T3 (es)	2018-01-18
NO20006328D0 (no)	2000-12-12
CA2334850C (en)	2013-11-26
SK288567B6 (sk)	2018-06-01
NZ509054A (en)	2004-01-30
DK2316924T3 (en)	2018-01-02
SK288544B6 (sk)	2018-03-05
IL140264A0 (en)	2002-02-10
EP2316923A2 (en)	2011-05-04
CA2334850A1 (en)	1999-12-16
WO1999064570A1 (en)	1999-12-16
DE69934885T2 (de)	2007-11-08
EP1086207A1 (en)	2001-03-28
PL398576A1 (pl)	2012-10-08
DK1085904T3 (da)	2013-02-25
EP1085904B1 (en)	2012-11-28
JP2002517229A (ja)	2002-06-18
WO1999064068A9 (en)	2000-03-09
PT1085904E (pt)	2013-03-05
EP2316924B1 (en)	2017-10-11
EP1086207B1 (en)	2007-01-17
EP2316924A2 (en)	2011-05-04
CN1312725A (zh)	2001-09-12
JP5081220B2 (ja)	2012-11-28
ES2281177T3 (es)	2007-09-16
US20160279227A1 (en)	2016-09-29
US6852522B1 (en)	2005-02-08
HUP0102441A2 (hu)	2001-10-28
US20120258134A1 (en)	2012-10-11
US20100158942A1 (en)	2010-06-24
CZ306637B6 (cs)	2017-04-12
AU770619B2 (en)	2004-02-26
US8765139B2 (en)	2014-07-01
IL140264A (en)	2008-03-20
EP1085904A1 (en)	2001-03-28
US6573079B1 (en)	2003-06-03
HUP0102441A3 (en)	2004-10-28
ATE351901T1 (de)	2007-02-15
PL200977B1 (pl)	2009-02-27
SK19072000A3 (sk)	2001-09-11
EP2316924A3 (en)	2014-03-19
AU4434599A (en)	1999-12-30
DK2316923T3 (en)	2018-01-08
ES2400445T3 (es)	2013-04-09
JP2010099081A (ja)	2010-05-06
IL140265A (en)	2008-06-05
JP2002517470A (ja)	2002-06-18
US7494808B2 (en)	2009-02-24
CZ302601B6 (cs)	2011-08-03
SK288200B6 (sk)	2014-06-03
BR9911163A (pt)	2002-01-15
DK1086207T3 (da)	2007-05-29
KR100637937B1 (ko)	2006-10-23
CA2334895C (en)	2016-01-19
US9352033B2 (en)	2016-05-31
KR20010052782A (ko)	2001-06-25
JP2014036654A (ja)	2014-02-27
EP1086207A4 (en)	2003-01-22
US6669943B1 (en)	2003-12-30
CZ20004635A3 (en)	2001-06-13
JP5810134B2 (ja)	2015-11-11
NZ509055A (en)	2004-02-27
AU771110B2 (en)	2004-03-11
US20040109877A1 (en)	2004-06-10
EP1085904A4 (en)	2004-12-29
IL140265A0 (en)	2002-02-10
KR20060080249A (ko)	2006-07-07
US20090203114A1 (en)	2009-08-13
DE69934885D1 (de)	2007-03-08
EP2316923B1 (en)	2017-10-18
US20140341948A1 (en)	2014-11-20
JP4531255B2 (ja)	2010-08-25
MXPA00012403A (es)	2003-05-15
AU4434399A (en)	1999-12-30
ES2653557T3 (es)	2018-02-07
JP2013226154A (ja)	2013-11-07
CA2334895A1 (en)	1999-12-16
US9387240B2 (en)	2016-07-12
PL219128B1 (pl)	2015-03-31

Legal Events

Date	Code	Title	Description
2010-04-19	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20006328L (no)	2001-02-02	Attenuerte negative tradvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter
WO2006083286A3 (en)	2007-01-25	Genetically engineered swine influenza virus and uses thereof
WO2006088481A3 (en)	2007-03-01	Genetically engineered equine influenza virus and uses thereof
NL300365I1 (nl)	2009-01-05	Recombinante influenzavirussen voor vaccins en gentherapie
BR9812232A (pt)	2000-07-18	Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
FI20001231A7 (fi)	2000-05-23	2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
EE05074B1 (et)	2008-10-15	Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
DE60130569D1 (de)	2007-10-31	Verpackung von replikon-partikeln eines positiv-strängigen rna-virus
EE05065B1 (et)	2008-08-15	Karbamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
MX342639B (es)	2016-10-07	Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
NO20091761L (no)	2000-06-02	Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
HUP0203056A1 (hu)	2002-12-28	Vakcinakészítmény
WO2002078631A3 (en)	2004-01-29	Improved conditionally replicating vectors for inhibiting viral infections
DE50110752D1 (de)	2006-09-28	Pneumovirus ns proteine antagonisieren die interferon (ifn) antwort
AU2003298578A1 (en)	2004-04-23	Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor
DE60330795D1 (de)	2010-02-11	Impfstoff gegen west nile virus
BR0101523A (pt)	2001-11-20	Pestivìrus, vacina, e, processos para imunizarcontra doença induzida por pestivìrus e parafabricar uma vacina para a proteção de um animalcontra um pestivìrus
NO20065853L (no)	2006-12-15	Hydrogelinterferonformuleringer
DK1192184T3 (da)	2007-04-30	Estere af surfaktantprotein C